AmerisourceBergen to buy Walgreens’ drug wholesale business for $6.5 billion
AmerisourceBergen has a sizable operation in North Texas.
Walgreens’s Alliance Healthcare businesses had combined revenue of about $19 billion in 2020.(Gene J. Puskar / AP)
By Wire Services
Updated at 10:50 a.m. Jan. 7 to remove references to Walgreens’s North Texas collaboration with Prime Therapeutics, which is unaffected.
Walgreens Boots Alliance will sell its pharmaceutical wholesale business to AmerisourceBergen in a $6.5 billion cash and stock deal.
Pharmaceutical wholesalers essentially act as middlemen, purchasing drugs from manufacturers and then distributing them to customers like drugstore chains.
Walgreens says it will now have the flexibility to invest in and focus on its retail business, which, like others, has been rattled by the COVID-19 pandemic.
Notice of incorrect information sent to some Washington health plan members
News provided by
Share this article
Share this article
EAGAN, Minn., Dec. 28, 2020 /PRNewswire/ Prime Therapeutics LLC (Prime) recently learned of a privacy incident that affected a subset of its covered members. Prime administers prescription drug benefits and provides total drug management solutions for health plans, employers, and government programs including Medicare and Medicaid. On Dec. 2, 2020, Prime became aware that certain letters to a subset of Boeing group health plan members, intended to inform recipients of changes to their 2021 prescription drug benefits, were mailed to the incorrect address and may have contained a limited amount of personal and medication information. These letters were mailed on Nov. 30, 2020.
Prime Therapeutics predictive model expands efforts to reduce potential misuse and abuse of opioids grandrapidsmn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from grandrapidsmn.com Daily Mail and Mail on Sunday newspapers.
Sobi appoints new Head of North America ahead of launch phase
News provided by
Share this article
Share this article
STOCKHOLM, Dec. 21, 2020 /PRNewswire/ Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has appointed Duane Barnes as the new Head of Sobi in North America. Sobi in North America has gone through significant change over the past few years and has exciting launches both underway and coming up in the years ahead, says Guido Oelkers, CEO and President of Sobi. This is why it is such a pleasure to welcome Duane to Sobi. His experience and background will be invaluable as we continue to build our presence in the US and fulfil our commitment to further expand access to patients.
Share:
EAGAN, Minn., Dec. 16, 2020 /PRNewswire/ In an effort to help assess the value of hemophilia A treatments relative to total health care costs and emergency department visits, Prime Therapeutics LLC (Prime) has finalized an arrangement with Takeda Pharmaceuticals America, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (NYSE:TAK) ( Takeda ) for the factor replacement product ADVATE
® [Antihemophilic Factor (Recombinant)], which is used in the treatment and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency).
Hemophilia treatment options have increased in recent years, including innovative therapies. However, these innovations come at a high price. Therefore, it is important to establish integrated medical and pharmacy benefit contracts between payers and product manufacturers on existing treatments. The arrangement between Prime and Takeda provides: